AMRX — Amneal Pharmaceuticals, Inc. stock price, charts and financials
QT72Amneal Pharmaceuticals, Inc.Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 37.31 | EPS (ttm) | 0.49 | Insider Own | - | Shs Outstand | 319.33M | Perf Week | 8.36% |
| Market Cap | 5.84B | Forward P/E | 15.58 | EPS next Y | 1.17 | Insider Trans | -0.25% | Shs Float | 163.57M | Perf Month | 0.49% |
| Enterprise Value | 8.49B | PEG | 1.71 | EPS next Q | 0.23 | Inst Own | - | Short Float | 6.46% | Perf Quarter | 12.29% |
| Income | 157.00M | P/S | 1.87 | EPS this Y | 106.71% | Inst Trans | - | Short Ratio | 5.33 | Perf Half Y | 47.54% |
| Sales | 3.12B | P/B | 49.89 | EPS next Y | 15.86% | ROA | 4.17% | Short Interest | 10.57M | Perf YTD | 45.08% |
| Book/sh | 0.37 | P/C | 45.61 | EPS next 5Y | 21.79% | ROE | -326.75% | 52W High | 19.26 -5.09% | Perf Year | 87.68% |
| Cash/sh | 0.40 | P/FCF | 65.36 | EPS past 3/5Y | - -18.45% | ROIC | 13.38% | 52W Low | 9.49 92.62% | Perf 3Y | 357.00% |
| Dividend Est. | - | EV/EBITDA | 12.99 | Sales past 3/5Y | 10.92% 8.66% | Gross Margin | 39.32% | Volatility | 4.87% 3.06% | Perf 5Y | 254.95% |
| Dividend TTM | - | EV/Sales | 2.72 | EPS Y/Y TTM | 228.95% | Oper. Margin | 12.93% | ATR (14) | 0.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.44 | Sales Y/Y TTM | 11.60% | Profit Margin | 5.05% | RSI (14) | 57.37 | Recom | 2.35 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.20 | EPS Q/Q | 20.00% | SMA20 | 3.87% | Beta | 1.22 | Target Price | 22.25 |
| Payout | 0.00% | Debt/Eq | 456.17 | Sales Q/Q | 9.79% | SMA50 | 2.72% | Rel Volume | 1.38 | Prev Close | 18.08 |
| Employees | 8,700 | LT Debt/Eq | 452.50 | Earnings | Oct 29 | SMA200 | 25.35% | Avg Volume | 1.99M | Price | 18.28 |
| IPO Date | May 07, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 34.81% 3.64% | Net Debt/EBITDA | 4.08 | Volume | 2,746,558 | Change | 1.11% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-26 | Reiterated | Barclays | Overweight | $16 → $20 |
| Sep-09-26 | Initiated | Leerink | Outperform | $23 |
| Aug-03-26 | Reiterated | UBS | Buy | $23 → $25 |
| Jul-31-26 | Reiterated | Goldman Sachs | Buy | $19 → $21 |
| Jul-15-26 | Reiterated | UBS | Buy | $19 → $23 |
| May-20-26 | Reiterated | Barclays | Overweight | $15 → $16 |
| Apr-17-26 | Initiated | UBS | Buy | $19 |
| Mar-02-26 | Reiterated | Truist Securities | Buy | $15 → $17 |
| Jan-07-26 | Reiterated | Truist Financial | Buy | $14 → $15 |
| Dec-08-25 | Initiated | Barclays | Overweight | $11 → $15 |
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,118 | 3,019 | 2,794 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,892 | 1,883 | 1,774 | — | — | — | — | — | — | |
| Gross Profit | 1,226 | 1,136 | 1,020 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 572 | 527 | 476 | — | — | — | — | — | — | |
| Research and Development | 177 | 186 | 191 | — | — | — | — | — | — | |
| Other Operating Expense | 74 | 0 | 104 | — | — | — | — | — | — | |
| Operating Income | 404 | 423 | 249 | — | — | — | — | — | — | |
| Interest Expense | 227 | 241 | 259 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 26 | -43 | -46 | — | — | — | — | — | — | |
| Net Income Before Taxes | 201 | 139 | -55 | — | — | — | — | — | — | |
| Income Taxes | -14 | 11 | 19 | — | — | — | — | — | — | |
| Consolidated Net Income | 157 | 72 | -117 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 216 | 128 | -74 | — | — | — | — | — | — | |
| Net Income | 157 | 72 | -117 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.50 | 0.23 | -0.38 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.50 | 0.23 | -0.38 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.49 | 0.22 | -0.38 | — | — | — | — | — | — | |
| EBITDA | 653 | 604 | 440 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 37.31 | 57.27 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.87 | 1.31 | 0.88 | — | — | — | — | — | — | |
| Gross Margin | 39.32 | 37.63 | 36.51 | — | — | — | — | — | — | |
| Operating Margin | 12.96 | 14.01 | 8.91 | — | — | — | — | — | — | |
| Net Margin | 5.04 | 2.38 | -4.19 | — | — | — | — | — | — | |
| Shares Outstanding | 319 | 313 | 309 | — | — | — | — | — | — | |
| Market Capitalization | 5,831 | 3,944 | 2,447 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BUCHI J KEVIN | Director | Sep 11 '26 | Option Exercise | 14.45 | 20,445 | 295,430 | 95,522 | Sep 14 |
| Kiely John | Director | Aug 13 '26 | Sale | 17.64 | 50,000 | 882,000 | 210,252 | Aug 14 |
| Daly Jason B. | EVP, Chief Legal Officer | Aug 12 '26 | Sale | 17.40 | 210,000 | 3,654,000 | 35,171 | Aug 13 |
| Shah Nikita | Executive Vice President | Aug 12 '26 | Sale | 17.51 | 146,403 | 2,563,517 | 253,390 | Aug 13 |
| Daly Jason B. | EVP, Chief Legal Officer | Aug 11 '26 | Sale | 17.70 | 6,613 | 117,050 | 245,171 | Aug 13 |
| BUCHI J KEVIN | Director | Aug 11 '26 | Option Exercise | 17.18 | 168,573 | 2,896,084 | 93,499 | Aug 13 |
| Autor Deborah M. | Director | May 11 '26 | Sale | 12.94 | 34,819 | 450,558 | 93,660 | May 12 |
| Yanai Shlomo | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 320,804 | May 08 |
| George Jeffrey P. | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 344,614 | May 08 |
| Patel Gautam | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 1,643,963 | May 08 |
| Kiely John | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 260,252 | May 08 |
| Nark Ted C | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 325,848 | May 08 |
| MEISTER PAUL M | Director | May 07 '26 | Option Exercise | 0.00 | 48,747 | 0 | 832,800 | May 08 |
| BUCHI J KEVIN | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 75,077 | May 08 |
| Autor Deborah M. | Director | May 07 '26 | Option Exercise | 0.00 | 34,819 | 0 | 128,479 | May 08 |